Perceptive Advisors is a privately owned hedge fund sponsor that finances the public equity markets across the globe.
Business Model:
Revenue: $13.7M
Employees: 51-200
Address: 499 Park Ave
City: New York
State: NY
Zip: 10022
Country: US
Perceptive Advisors, LLC is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while making its investments. The firm typically invests in biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York, New York.
Contact Phone:
+16462055340
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
8/2017 | Dova Pharmaceuticals | Post-IPO Equity | - |
5/2017 | Synlogic | Series C | 42M |
1/2019 | Vyome Therapeutics | Series D | 22M |
7/2020 | Genome Medical | Series B | 0 |
8/2020 | ReViral | Series C | 0 |
7/2020 | Cogent Biosciences | Post-IPO Equity | 104.4M |
2/2018 | Partner Therapeutics | Series A | 60M |
4/2022 | Surf Bio | Seed | 16M |
10/2018 | Stoke Therapeutics | Series B | 90M |
12/2020 | Solid Biosciences | Post-IPO Equity | 0 |
2/2015 | Cidara Therapeutics | Series B | 42M |
7/2015 | Outlook Therapeutics | Venture Round | 31M |
4/2018 | Eidos Therapeutics | Series B | 0 |
12/2005 | EUSA Pharma | Venture Round | 0 |
11/2020 | Adagio Medical | Series E | 0 |
6/2022 | Cerebral Therapeutics | Series C | 40M |
6/2015 | Alliqua BioMedical | Post-IPO Debt | 15.5M |
4/2020 | COMPASS Pathways | Series B | 0 |
9/2021 | SomaLogic | Post-IPO Equity | 0 |
2/2022 | Beta Bionics | Series C | 0 |
9/2021 | Emulate | Series E | 82M |
2/2022 | Omada Health | Series E | 0 |
9/2014 | Affimed | Debt Financing | 14M |
7/2016 | Ardelyx | Post-IPO Equity | 0 |
5/2017 | Home Dialysis Plus | Series C | 76.5M |
9/2020 | Willow | Series C | 0 |
10/2021 | Honor | Debt Financing | 300M |
4/2021 | Forge Biologics | Series B | 120M |
7/2019 | Frequency Therapeutics | Series C | 0 |
9/2018 | Lyra Therapeutics | Series B | 0 |
6/2020 | C4 Therapeutics | Series B | 150M |
5/2016 | AVEO Oncology | Post-IPO Equity | 17M |
12/2015 | Clearside Biomedical | Series C | 20M |
9/2021 | Hancock Jaffe Laboratories | Post-IPO Equity | 20M |
1/2016 | Arno Therapeutics | Post-IPO Equity | 0 |
3/2015 | Minerva Neuroscience | Post-IPO Equity | 0 |
7/2018 | Alector | Series E | 133M |
3/2018 | IDEAYA Biosciences | Series B | 0 |
8/2016 | Arno Therapeutics | Post-IPO Equity | 8M |
12/2019 | Quellis Biosciences | Series A | 0 |
10/2021 | Science 37 | Post-IPO Equity | 0 |
6/2020 | 4D Molecular Therapeutics | Series C | 0 |
7/2014 | Virobay | Series B | 8M |
1/2022 | Orchestra BioMed | Series D | 0 |
10/2022 | immatics biotechnologies | Post-IPO Equity | 0 |
3/2020 | immatics biotechnologies | Post-IPO Equity | 0 |
1/2022 | AvengeBio | Series A | 0 |
9/2021 | A-Alpha Bio | Series A | 20M |
6/2019 | PanTheryx | Venture Round | 50M |
7/2019 | Neptune Wellness Solutions | Post-IPO Equity | 41.4M |
5/2017 | Xontogeny | Series A | 15M |
3/2015 | Champions Oncology | Post-IPO Equity | 14M |
5/2019 | ArcherDX | Series B | 60M |
12/2019 | Zentalis Pharmaceuticals | Series C | 85M |
9/2017 | BridgeBio Pharma | Series C | 135M |
2/2020 | Agile Therapeutics | Post-IPO Debt | 20M |
12/2019 | ArcherDX | Series C | 0 |
9/2018 | Vapotherm | Series D | 0 |
11/2015 | Solid Biosciences | Series B | 42.5M |
12/2021 | Mythic Therapeutics | Series B | 0 |
11/2020 | Prometheus Biosciences | Equity | 130M |
4/2020 | Dynacure | Series C | 54.2M |
9/2020 | Zymergen | Series D | 300M |
3/2021 | Pyxis Oncology | Series B | 152M |
2/2018 | PROCEPT BioRobotics | Series E | 0 |
5/2018 | MEI Pharma | Post-IPO Equity | 75M |
10/2021 | Twin Health | Series C | 155M |
1/2021 | Impulse Dynamics | Series D | 60M |
4/2019 | Fusion Pharmaceuticals | Series B | 0 |
6/2021 | PROCEPT BioRobotics | Series G | 0 |
7/2015 | GenSight Biologics | Series B | 0 |
1/2021 | Earli | Series A | 40M |
11/2017 | Counsyl | Equity | 80M |
5/2017 | Outset Medical | Series C | 0 |
6/2020 | DNAnexus | Series G | 0 |
6/2020 | Fulcrum Therapeutics | Post-IPO Equity | 0 |
5/2020 | Nautilus Biotechnology | Series B | 76M |
5/2021 | Cue | Venture Round | 235M |
3/2019 | Saama | Venture Round | 40M |
10/2020 | LianBio | Series A | 0 |
6/2016 | VitalConnect | Series B | 18M |
7/2018 | Athenex | Post-IPO Equity | 50M |
3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
4/2019 | Kindbody | Series A | 15M |
9/2020 | I-Mab Biopharma | Post-IPO Equity | 0 |
1/2020 | Sonendo | Venture Round | 85M |
12/2016 | VBI Vaccines | Post-IPO Equity | 10.6M |
12/2019 | Black Diamond Therapeutics | Series C | 0 |
7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
7/2021 | Sema4 | Post-IPO Equity | 350M |
5/2018 | Rain Therapeutics | Series A | 18.4M |
12/2016 | VBI Vaccines | Post-IPO Debt | 13M |
3/2023 | CARGO Therapeutics | Series A | 0 |
1/2019 | Black Diamond Therapeutics | Series B | 85M |
4/2017 | Singulex | Debt Financing | 50M |
1/2021 | Clover Health | Post-IPO Equity | 400M |
1/2018 | AEGEA Medical | Series D | 0 |
5/2021 | NiKang Therapeutics | Series C | 200M |
8/2019 | Landos Biopharma | Series B | 60M |
8/2020 | Freenome | Series C | 270M |
9/2022 | InSightec | Debt Financing | 100M |
9/2017 | Landos Biopharma | Series A | 10M |
6/2020 | C4 Therapeutics | Debt Financing | 20M |
8/2018 | Outset Medical | Series D | 0 |
8/2021 | Bridge to Life | Venture Round | 56M |
7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
2/2019 | ADMA Biologics | Post-IPO Debt | 72.5M |
11/2015 | Celladon | Post-IPO Equity | 39.5M |
8/2016 | Vyome Therapeutics | Series C | 14M |
5/2020 | Omada Health | Venture Round | 57M |
9/2022 | SpringWorks Therapeutics | Post-IPO Equity | 225M |
10/2014 | Zynerba Pharmaceuticals | Venture Round | 13M |
9/2020 | Rain Therapeutics | Series B | 63M |
1/2020 | Cerebral Therapeutics | Series B | 35M |
1/2018 | Vitruvias Therapeutics | Series A | 11.5M |
3/2021 | Scribe Therapeutics | Series B | 100M |
7/2020 | Pear Therapeutics | Debt Financing | 50M |
6/2015 | Outset Medical | Debt Financing | 45M |
10/2013 | Arno Therapeutics | Post-IPO Equity | 0 |
8/2018 | ReViral | Series B | 0 |
11/2021 | Sermonix | Series A | 40M |
12/2021 | Freenome | Series D | 300M |
7/2016 | VBI Vaccines | Post-IPO Equity | 0 |
5/2019 | Athenex | Post-IPO Equity | 100M |
9/2015 | Outlook Therapeutics | Venture Round | - |
6/2020 | AsclepiX Therapeutics | Series A | 35M |
4/2018 | Kodiak Sciences | Convertible Note | 33M |
1/2021 | DarioHealth | Post-IPO Equity | 70M |
1/2022 | Ceptur Therapeutics | Series A | 0 |
3/2022 | VivoSense | Series A | 0 |
11/2022 | Biodesix | Post-IPO Debt | 50M |
9/2016 | Establishment Labs | Debt Financing | 15M |
7/2019 | Foamix | Post-IPO Debt | 64M |
1/2021 | Affinivax | Series C | 226M |
7/2020 | Verona Pharma | Private Placement | 200M |
7/2020 | Thrive Earlier Detection | Series B | 0 |
8/2017 | Molecular Templates | Post-IPO Equity | 60M |
12/2016 | Motus GI | Venture Round | 0 |
7/2019 | Kronos Bio | Series A | 105M |
4/2022 | Lyra Therapeutics | Post-IPO Equity | 0 |
4/2019 | Poseida Therapeutics | Series C | 0 |
9/2018 | 4D Molecular Therapeutics | Series B | 0 |
12/2020 | Neuron23 | Series B | 80M |
12/2016 | Vensun Pharmaceuticals | Series C | 22.5M |
2/2022 | Synthego | Series E | 0 |
7/2020 | Kindbody | Series B | 0 |
8/2021 | Zentera Therapeutics | Series B | 75M |
2/2021 | Day One Biopharmaceuticals | Series B | 130M |
5/2007 | Spectrum Pharmaceuticals | Post-IPO Equity | 0 |
8/2014 | Bellicum Pharmaceuticals | Series C | 55M |
10/2020 | AavantiBio | Series A | 0 |
1/2020 | Lyra Therapeutics | Series C | 0 |
5/2020 | Atea | Series D | 215M |
7/2020 | Forge Biologics | Series A | 40M |
5/2021 | Juno Diagnostics | Series A | 25M |
2/2021 | Nuvation Bio | Post-IPO Equity | 502M |
10/2014 | Invitae | Series F | 0 |
3/2019 | Orchestra BioMed | Series B | 34M |
12/2022 | Apogee Therapeutics | Series B | 0 |
3/2022 | DNAnexus | Series H | 200M |
7/2019 | Beta Bionics | Series B | 63M |
1/2019 | BridgeBio Pharma | Equity | 299.2M |
10/2016 | True North Therapeutics | Series D | 45M |
2/2022 | Endeavor BioMedicines | Series B | 101M |
8/2020 | Kronos Bio | Private Equity Round | 155M |
7/2019 | Freenome | Series B | 160M |
11/2015 | Vapotherm | Series C | 0 |
4/2019 | SpringWorks Therapeutics | Series B | 125M |
11/2020 | Achilles Therapeutics | Series C | 69.8M |
9/2020 | Escient Pharmaceuticals | Series B | 77.5M |
4/2014 | Otonomy | Series D | 49M |
5/2023 | OnKure Therapeutics | Series C | 0 |
8/2021 | Genome Medical | Series C | 0 |
6/2019 | Genome Medical | Series B | 23M |
3/2022 | Neuron23 | Series C | 0 |
2/2021 | Pipeline Therapeutics | Series C | 0 |
11/2022 | Zenas BioPharma | Series B | 0 |
6/2020 | Athira Pharma | Series B | 85M |
5/2023 | Lyra Therapeutics | Post-IPO Equity | 0 |
9/2019 | Achilles Therapeutics | Series B | 120.9M |
5/2021 | Affinia Therapeutics | Series B | 0 |
7/2021 | Point Biopharma | Post-IPO Equity | 0 |
9/2022 | Solid Biosciences | Post-IPO Equity | 75M |
4/2021 | Icosavax | Series B | 0 |
11/2021 | Acrivon Therapeutics | Series B | 0 |
3/2017 | Solid Biosciences | Series C | 0 |
8/2020 | Taysha Gene Therapies | Series B | 0 |
11/2019 | Avidity Biosciences | Series C | 0 |
1/2021 | MIVI Neuroscience | Series B | 35M |
3/2021 | Crossover Health | Series D | 0 |
9/2021 | HilleVax | Equity | 135M |
8/2019 | Oncorus | Series B | 0 |
6/2015 | CytomX Therapeutics | Series D | 70M |
3/2021 | Graphite Bio | Series B | 150.7M |
6/2021 | RayzeBio | Series C | 108M |
12/2021 | Hyperfine | Post-IPO Equity | 0 |
7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
1/2016 | Zymeworks | Series A | 0 |
12/2018 | Relay Therapeutics | Series C | 0 |
6/2021 | Kindbody | Series C | 0 |
5/2019 | Confo Therapeutics | Series A | 33.6M |
6/2021 | Nautilus Biotechnology | Post-IPO Equity | 0 |
5/2017 | Vapotherm | Series D | 0 |
12/2015 | True North Therapeutics | Series C | 40M |
1/2021 | Beam Therapeutics | Post-IPO Equity | 260M |
3/2021 | OnKure | Series B | 56.6M |
8/2018 | Orchard Therapeutics | Series C | 0 |
11/2014 | Blueprint Medicines | Series C | 50M |
10/2021 | CinCor Pharma | Series B | 0 |
3/2010 | Sevion Therapeutics | Post-IPO Equity | 0 |
9/2018 | Allogene | Convertible Note | 0 |
1/2021 | IsoPlexis | Series D | 85M |
6/2020 | CereVasc | Series A | 44M |
8/2020 | Metabolon | Venture Round | 72M |
8/2022 | MeiraGTx | Post-IPO Debt | 75M |
6/2016 | Corbus Pharmaceuticals | Post-IPO Equity | 14.8M |
4/2021 | Renovia | Series C | 0 |
1/2021 | IsoPlexis | Debt Financing | 50M |
11/2018 | Medicrea | Post-IPO Debt | 30M |
3/2020 | Zucara Therapeutics | Series A | 21M |
3/2021 | Absci | Venture Round | 0 |
3/2018 | Molecular Templates | Post-IPO Debt | 10M |
5/2015 | REGENXBIO | Series D | 0 |
8/2018 | Renovia | Series B | 32.3M |
8/2016 | Aquestive Therapeutics | Debt Financing | 50M |
7/2019 | AgaMatrix | Debt Financing | 56M |
8/2022 | MeiraGTx | Post-IPO Debt | 0 |
6/2022 | Cerebral Therapeutics | Series C | 0 |
4/2022 | Surf Bio | Seed Round | 0 |
4/2022 | Lyra Therapeutics | Post-IPO Equity | 0 |
3/2022 | VivoSense | Series A | 0 |
3/2022 | Neuron23 | Series C | 0 |
3/2022 | DNAnexus | Series H | 0 |
2/2022 | Omada Health | Series E | 0 |
2/2022 | Synthego | Series E | 0 |
2/2022 | Beta Bionics | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|